Genprex (GNPX) Total Current Liabilities (2016 - 2026)
Genprex (GNPX) posted quarterly Total Current Liabilities of $3.4 million for Q1 2026, up 56.57% year-over-year from $2.1 million in Q1 2025, and up 54.21% quarter-over-quarter from $2.2 million in Q4 2025.
Genprex (GNPX) Total Current Liabilities (2016 - 2026) Analysis & Trends
Genprex's Total Current Liabilities history runs 11 years deep, the most recent figure standing at $3.4 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 56.57% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $3.4 million (up 56.57% YoY), while the FY2025 annual figure was $2.2 million, down 13.16% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $3.4 million, up from $2.2 million in the prior quarter.
- The five-year high for Total Current Liabilities was $4.8 million in Q1 2023, with the low at $2.1 million in Q1 2025.
- The 5-year median for Total Current Liabilities is $2.5 million (2024), against an average of $2.9 million.
- The sharpest annual moves came in 2022 and 2024: Total Current Liabilities surged 288.64% in 2022, then tumbled 48.31% in 2024.
- Genprex's Total Current Liabilities stood at $2.8 million in 2022, then rose by 15.8% to $3.3 million in 2023, then declined by 23.05% to $2.5 million in 2024, then dropped by 13.16% to $2.2 million in 2025, then jumped by 54.21% to $3.4 million in 2026.
- Business Quant data shows GNPX's Total Current Liabilities at $3.4 million in Q1 2026, $2.2 million in Q4 2025, and $2.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 630.93 Mn |
| 10 | Genprex | 1.97 Mn | -13.19 Mn | - | 2.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.35 Mn |
| Dec 31, 2025 | 2.17 Mn |
| Sep 30, 2025 | 2.55 Mn |
| Jun 30, 2025 | 2.44 Mn |
| Mar 31, 2025 | 2.14 Mn |
| Dec 31, 2024 | 2.50 Mn |
| Sep 30, 2024 | 2.24 Mn |
| Jun 30, 2024 | 2.26 Mn |
| Mar 31, 2024 | 3.81 Mn |
| Dec 31, 2023 | 3.25 Mn |
| Sep 30, 2023 | 4.34 Mn |
| Jun 30, 2023 | 3.86 Mn |
| Mar 31, 2023 | 4.84 Mn |
| Dec 31, 2022 | 2.81 Mn |
| Sep 30, 2022 | 2.46 Mn |
| Jun 30, 2022 | 2.15 Mn |
| Mar 31, 2022 | 2.38 Mn |
| Dec 31, 2021 | 1.59 Mn |
| Sep 30, 2021 | 1.16 Mn |
| Jun 30, 2021 | 1.05 Mn |